A Comparative Trial of Two Formulations of Clomipramine

1972 ◽  
Vol 1 (1) ◽  
pp. 30-36 ◽  
Author(s):  
G Beaumont ◽  
J Seldrup
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Clinical Response ◽  
Clinical Improvement ◽  
General Practitioners ◽  
Rating Scale ◽  
Drug Effects ◽  
Comparative Trial ◽  
Good Clinical Response ◽  
Clinical Rating Scale

In a multi-centre clinical trial comparing two formulations of Clomipramine (Anafranil® Geigy) thirty General Practitioners provided two hundred and seven patients. One hundred and forty nine patients completed the study. No difference was found between a capsule and a tablet formulation in terms of tolerance and efficacy. Using a clinical rating scale the total score for twelve symptoms fell from a mean of 18 .2 to 5.5 and 6.0 in the capsule and tablet groups respectively. By recording the presence of symptoms subsequently to be regarded as side effects before admission to the trial many so called drug effects were found to be present before commencing treatment. The forty patients who dropped out of the trial because of intolerable side effects also failed to show any clinical improvement and appeared to constitute a separate group from those who completed the trial and who showed good clinical response in association with a diminishing number of side effects.

A Comparative Trial of Opipramol and Chlordiazepoxide in the Treatment of Anxiety

1973 ◽  
Vol 1 (3) ◽  
pp. 145-150 ◽  
Author(s):  
K Jepson ◽  
G Beaumont
Keyword(s):  
Clinical Trial ◽  
General Practice ◽  
Side Effects ◽  
Rating Scale ◽  
Comparative Trial ◽  
Anxiety Score ◽  
Double Blind ◽  
Somatic Anxiety ◽  
Daily Dose ◽  
The Difference

A daily dose of 200 mg of opipramol (Insidon, Geigy) and 30 mg of chlordiazepoxide (Librium, Roche) were compared in a clinical trial in general practice. The trial was double blind and a stratified randomisation technique was employed. Twenty four patients received opipramol and twenty six chlordiazepoxide for four weeks. A total anxiety score and separate ‘psychic’ anxiety and ‘somatic’ anxiety scores were recorded, using a rating scale initially and after two and four weeks treatment. No overall difference in efficacy was found between the two drugs—opipramol producing a 76% improvement and chlordiazepoxide 64% by the end of the study. There was no difference in the relief of psychic anxiety. Although opipramol appeared to give more relief of somatic anxiety, the difference was not statistically significant. Again although opipramol relieved more individual symptoms than chlordiazepoxide, none of the differences were significant. 70% of patients on opipramol and 74% of those on chlordiazepoxide were classified ‘better’ globally by both doctor and patient by the end of the trial. The total number of side effects recorded was similar on both drugs although drowsiness occurred twice as frequently on chlordiazepoxide as it did on opipramol.

Single-Dose Treatment of Trichomonal Vaginitis: A Comparison of Tinidazole and Metronidazole

1973 ◽  
Vol 1 (2) ◽  
pp. 438-441
Author(s):  
R Anjaneyulu ◽  
S A Gupte ◽  
D B Desai
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Clinical Response ◽  
Clinical Improvement ◽  
Statistical Evaluation ◽  
Comparative Trial ◽  
Dose Treatment ◽  
Satisfactory Clinical Response ◽  
Single Dose Treatment ◽  
Better Than

A randomized, comparative trial was carried out in 100 patients with trichomonal vaginitis to compare the efficacy and toleration of a single 2 g dose of tinidazole and metronidazole. Tinidazole produced parasitological cure in 94% of patients (47/50) and a satisfactory clinical response in 96% of patients (48/50); for metronidazole the figures were 64% (32/50) and 72% (36/50) respectively. Side-effects were reported by 52% of patients (26/50) on tinidazole and 82% of patients (41/50) on metronidazole. Severity of side-effects and their frequency per patient were significantly less (p<0.05 to 0.01) with tinidazole than with metronidazole. Statistical evaluation of the results showed that tinidazole was significantly better than metronidazole with respect to parasitological cure (p<0.01) and clinical improvement (p<0.01) and also with regard to the incidence and intensity of side effects (p<0.01).

A Controlled Comparative Trial of a Combination of Opipramol and Clomipramine and a Higher Dose of Clomipramine Alone

1975 ◽  
Vol 3 (1) ◽  
pp. 26-31
Author(s):  
J E Murphy ◽  
J F Donald ◽  
G Beaumont
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Combination Therapy ◽  
Rating Scale ◽  
Comparative Trial ◽  
Combination Group ◽  
Controlled Clinical Trial ◽  
Dose Regime ◽  
Symptom Rating ◽  
Depressive States

Sixty patients suffering from mixed anxiety depressive states were admitted to a comparative controlled clinical trial of a free combination of opipramol 50 mg and clomipramine 10 mg and clomipramine 25 mg. A double-dummy technique was used to ensure blindness and both regimes were administered three times daily. A stratified randomization technique was employed but this did not work effectively as far as severity was concerned producing some imbalance in the groups. Thirty-one patients received the combination therapy and 29 clomipramine alone. Twenty-eight patients on the combination regime and 24 on clomipramine alone completed the study. Amongst the completers the total score, on a 17 symptom rating scale, fell from 19·6 to 6·6 in the combination group and from 23·6 to 9·3 in the clomipramine alone group after 4 weeks treatment. Significantly more side-effects, especially dry mouth, were seen in the clomipramine alone group. After 2 weeks the opipramol/clomipramine regime was significantly more effective in the relief of anxiety whereas the clomipramine higher dose regime brought about a significantly greater improvement in the symptom depressed mood.

A Multicentric Clinical Trial Comparing Otocerol® with Cerumol® as Cerumenolytics

1978 ◽  
Vol 6 (3) ◽  
pp. 241-244 ◽  
Author(s):  
Gabriel Jaffé ◽  
Jack Grimshaw
Keyword(s):  
Clinical Trial ◽  
General Practitioners ◽  
Comparative Trial ◽  
Double Blind ◽  
Better Than

Fifteen general practitioners conducted a randomized, double-blind comparative trial of two cerumenolytics, namely, Otocerol® and Cerumol®. A total of 106 patients were entered into the study (fifty-three in each group). Otocerol was shown to be marginally better than Cerumol in all parameters evaluated.

A Clinical Trial of ICI 58,834 – A Potential Anti-Depressant

1973 ◽  
Vol 1 (7) ◽  
pp. 624-626 ◽  
Author(s):  
Malcolm Peet
Keyword(s):  
Clinical Trial ◽  
Clinical Response ◽  
Rating Scale ◽  
Controlled Trial ◽  
Antidepressant Activity ◽  
Depressive Illness ◽  
Blood Levels ◽  
Significant Difference ◽  
Single Blind ◽  
Hamilton Rating Scale

Twenty-four in-patients with depressive illness were treated with either ICI 58,834 or imipramine for twenty-one days in a single-blind controlled trial. No statistically significant difference in response was found between the two groups, as assessed by the Hamilton Rating Scale and the Beck Depression Inventory. Blood levels of ICI 58,834 at one hour were not correlated with clinical response. Nausea and vomiting occurred in three patients taking ICI 58,834. It is concluded that further investigation of the apparent antidepressant activity of this new drug is indicated.

A Comparative Trial of Minocin (Minocycline Hydrochloride) and Ampicillin in the Treatment of Acute Exacerbations of Chronic Bronchitis

1975 ◽  
Vol 3 (5) ◽  
pp. 304-308 ◽  
Author(s):  
G R F Burrow ◽  
A S Fox ◽  
R J E Daniel
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Chronic Bronchitis ◽  
Therapeutic Efficacy ◽  
Comparative Trial ◽  
Double Blind ◽  
Significant Difference ◽  
Acute Exacerbations ◽  
Minocycline Hydrochloride ◽  
Long Acting

One hundred and fifteen patients suffering from acute exacerbations of chronic bronchitis took part in a double-blind, multicentre, clinical trial designed to compare the therapeutic efficacy and tolerability of ampicillin and minocycline hydrochloride, a new, long-acting, semi-synthetic tetracycline. Both antibiotics were equally successful in treatment, there being no statistically significant difference between the two in any of the parameters studied. Side-effects were few and far between. Only one patient out of the 57 who took minocycline, complained of dizziness.

scholarly journals Predictors of clinical response after rTMS treatment of patients suffering from drug-resistant depression

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Aurélie Lacroix ◽  
Benjamin Calvet ◽  
Benjamin Laplace ◽  
Marilyne Lannaud ◽  
Brigitte Plansont ◽  
...  
Keyword(s):  
Clinical Response ◽  
Clinical Improvement ◽  
Depressive Episode ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Routine Practice ◽  
Drug Resistant ◽  
Therapeutic Choice ◽  
Resistant Depression ◽  
Success Of Treatment

AbstractRepeated transcranial magnetic stimulation (rTMS) is a therapeutic brain-stimulation technique that is particularly used for drug-resistant depressive disorders. European recommendations mention the effectiveness of 30 to 64%. The failure rate of treatment is high and clinical improvement is visible only after a certain period of time. It would thus be useful to have indicators that could anticipate the success of treatment and more effectively guide therapeutic choices. We aimed to find predictive indicators of clinical improvement at 1 month after the start of rTMS treatment among the data collected during the care of patients with drug-resistant depression included in the Neuromodulation Unit of the Esquirol Hospital in Limoges since 2007. In total, 290 patients with a pharmaco-resistant depressive episode, according to the Hamilton Depression Rating Scale (HDRS) (score ≥8), before treatment who underwent a complete course of rTMS treatment and did not object to the use of their collected data were included. The clinical response in routine practice, corresponding to a decrease in the HDRS score of at least 50% from inclusion, was determined and complemented by interquartile analysis. A combination of factors predictive of clinical response during care, such as a short duration of the current depressive episode associated with a higher HDRS agitation item value (or a lower perceived sleepiness value) and a higher number of previous rTMS treatments, were identified as being useful in predicting the efficacy of rTMS treatment in routine clinical practice, thus facilitating the therapeutic choice for patients with drug-resistant depression.

A Comparative Trial of a New Antidepressant, Fluoxetine

1987 ◽  
Vol 150 (5) ◽  
pp. 653-655 ◽  
Author(s):  
S. Levine ◽  
R. Deo ◽  
K. Mahadevan
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Comparative Trial ◽  
Single Daily Dose ◽  
Weight Increase ◽  
Positive Correlation ◽  
Daily Dose

This clinical trial of a new antidepressant, fluoxetine, shows it to be as effective as a standard tricyclic drug, imipramine. It is effective as a single daily dose and is free of any significant side-effects. It is less sedative and appears to cause fewer problems of weight increase. The three scales used to assess efficacy showed a very positive correlation.

A Single-Blind Comparative Clinical Trial of Lymecycline and Amoxycillin in the Treatment of Acute Bronchitis in General Practice

1976 ◽  
Vol 4 (1) ◽  
pp. 64-68 ◽  
Author(s):  
J E Murphy ◽  
J F Donald ◽  
A L Molla
Keyword(s):  
Clinical Trial ◽  
General Practice ◽  
Side Effects ◽  
General Practitioners ◽  
Statistical Significance ◽  
Acute Bronchitis ◽  
Sputum Volume ◽  
Blind Comparison ◽  
Single Blind ◽  
Symptoms And Signs

A single-blind comparison of lymecycline and amoxycillin was performed by three general practitioners in the treatment of acute bronchitis, A total of 132 patients were treated for seven days with lymecycline (204 mg) two capsules twice daily or amoxycillin 250 mg three times daily. Symptoms and signs assessed were cough, dyspnoea, sputum volume, purulence of sputum and temperature. Both drugs brought about a statistically significant improvement. For all parameters the improvements seen with lymecycline were superior to those seen with amoxycillin although in no case did any of these reach statistical significance. However, in the case of purulent sputum those patients receiving lymecycline showed improvement which reached borderline significance (0.05 < p < 0.1) as compared with amoxycillin. Side-effects in the case of both drugs were negligible.

A Comparative Clinical Trial of Mianserin (Norval®) and Amitriptyline in the Treatment of Depression in General Practice

1978 ◽  
Vol 6 (3) ◽  
pp. 199-206 ◽  
Author(s):  
J Eric Murphy ◽  
K M Bridgman
Keyword(s):  
Clinical Trial ◽  
General Practice ◽  
Side Effects ◽  
Comparative Trial ◽  
Double Blind ◽  
Comparative Clinical Trial ◽  
Treatment Of Depression

A double-blind controlled comparative trial of mianserin (Norval®) and amitriptyline was conducted in general practice. Fifty-one patients were treated with amitriptyline and fifty-five with mianserin. The dosage for the first week was 25 mg t.d.s. for amitriptyline and 10 mg t.d.s. for mianserin, increasing to 50 mg t.d.s. and 20 mg t.d.s. respectively for the subsequent three weeks. Both drugs proved equally effective in relieving the symptoms of primary depression but mianserin showed a reduced incidence of side-effects which was statistically significant.

Sign in / Sign up

Export Citation Format

Share Document